702 related articles for article (PubMed ID: 18059533)
1. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Sekhavat A; Sun JM; Davie JR
Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
[TBL] [Abstract][Full Text] [Related]
2. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
Zhao S; Venkatasubbarao K; Li S; Freeman JW
Cancer Res; 2003 May; 63(10):2624-30. PubMed ID: 12750289
[TBL] [Abstract][Full Text] [Related]
3. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
[TBL] [Abstract][Full Text] [Related]
5. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
6. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression.
Wu Y; Zhang X; Salmon M; Zehner ZE
Genes Cells; 2007 Aug; 12(8):905-18. PubMed ID: 17663720
[TBL] [Abstract][Full Text] [Related]
7. Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site.
Gao J; Chen T; Liu J; Liu W; Hu G; Guo X; Yin B; Gong Y; Zhao J; Qiang B; Yuan J; Peng X
Glia; 2009 Jul; 57(9):989-99. PubMed ID: 19062177
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells.
Hou M; Wang X; Popov N; Zhang A; Zhao X; Zhou R; Zetterberg A; Björkholm M; Henriksson M; Gruber A; Xu D
Exp Cell Res; 2002 Mar; 274(1):25-34. PubMed ID: 11855854
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase activity in conjunction with E2F-1 and p53 regulates Apaf-1 expression in 661W cells and the retina.
Wallace DM; Cotter TG
J Neurosci Res; 2009 Mar; 87(4):887-905. PubMed ID: 18951482
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Law AY; Lai KP; Lui WC; Wan HT; Wong CK
Exp Cell Res; 2008 Oct; 314(16):2975-84. PubMed ID: 18652825
[TBL] [Abstract][Full Text] [Related]
12. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
13. Modulation of immunoglobulin gene conversion frequency and distribution by the histone deacetylase HDAC2 in chicken DT40.
Lin W; Hashimoto S; Seo H; Shibata T; Ohta K
Genes Cells; 2008 Mar; 13(3):255-68. PubMed ID: 18298800
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Frønsdal K; Saatcioglu F
Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
[TBL] [Abstract][Full Text] [Related]
16. Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer.
Dressel U; Renkawitz R; Baniahmad A
Anticancer Res; 2000; 20(2A):1017-22. PubMed ID: 10810390
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor Trichostatin A reduces anti-DNA autoantibody production and represses IgH gene transcription.
Lu ZP; Ju ZL; Shi GY; Zhang JW; Sun J
Biochem Biophys Res Commun; 2005 Apr; 330(1):204-9. PubMed ID: 15781251
[TBL] [Abstract][Full Text] [Related]
18. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex.
Zhang Y; Dufau ML
J Biol Chem; 2002 Sep; 277(36):33431-8. PubMed ID: 12091390
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase 3 represses HTLV-1 tax transcription.
Villanueva R; Iglesias AH; Camelo S; Sanin LC; Gray SG; Dangond F
Oncol Rep; 2006 Sep; 16(3):581-5. PubMed ID: 16865259
[TBL] [Abstract][Full Text] [Related]
20. The interaction with Sp1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL-1 alpha in human melanoma cells.
Enya K; Hayashi H; Takii T; Ohoka N; Kanata S; Okamoto T; Onozaki K
J Leukoc Biol; 2008 Jan; 83(1):190-9. PubMed ID: 17906119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
